Source 1primary paper2026MED
Toolkit/engineered virus-like particles
engineered virus-like particles
Also known as: eVLPs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Engineered virus-like particles (eVLPs) have emerged as a promising class of delivery systems for genome editing agents.
Usefulness & Problems
Why this is useful
eVLPs are delivery systems for genome editing agents that enable transient delivery of ribonucleoprotein cargos such as Cas9, base editors, and prime editors. The abstract frames them as combining viral-like entry with nonviral safety advantages.; delivery of genome editing agents; transient delivery of ribonucleoproteins; cell-type-specific targeting via pseudotyping
Source:
eVLPs are delivery systems for genome editing agents that enable transient delivery of ribonucleoprotein cargos such as Cas9, base editors, and prime editors. The abstract frames them as combining viral-like entry with nonviral safety advantages.
Source:
delivery of genome editing agents
Source:
transient delivery of ribonucleoproteins
Source:
cell-type-specific targeting via pseudotyping
Problem solved
The platform addresses delivery of genome editing proteins while aiming to retain efficient cellular entry and improve safety relative to viral vectors. It also supports transient rather than persistent editor exposure.; combining efficient cellular entry with nonviral safety advantages; delivery of Cas9, base editor, and prime editor ribonucleoproteins
Source:
The platform addresses delivery of genome editing proteins while aiming to retain efficient cellular entry and improve safety relative to viral vectors. It also supports transient rather than persistent editor exposure.
Source:
combining efficient cellular entry with nonviral safety advantages
Source:
delivery of Cas9, base editor, and prime editor ribonucleoproteins
Problem links
combining efficient cellular entry with nonviral safety advantages
LiteratureThe platform addresses delivery of genome editing proteins while aiming to retain efficient cellular entry and improve safety relative to viral vectors. It also supports transient rather than persistent editor exposure.
Source:
The platform addresses delivery of genome editing proteins while aiming to retain efficient cellular entry and improve safety relative to viral vectors. It also supports transient rather than persistent editor exposure.
delivery of Cas9, base editor, and prime editor ribonucleoproteins
LiteratureThe platform addresses delivery of genome editing proteins while aiming to retain efficient cellular entry and improve safety relative to viral vectors. It also supports transient rather than persistent editor exposure.
Source:
The platform addresses delivery of genome editing proteins while aiming to retain efficient cellular entry and improve safety relative to viral vectors. It also supports transient rather than persistent editor exposure.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
pseudotyping-mediated cell-type targetingribonucleoprotein deliverytransient cargo deliveryTranslation ControlTechniques
Computational DesignTarget processes
editingtranslationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: externally suppliedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: delivery
The abstract indicates that eVLP use depends on structural and production principles, particle assembly, cargo stability, and pseudotyping approaches for targeting. Specific components or production reagents are not given in the provided text.; requires particle assembly and cargo stabilization; targeting versatility depends on pseudotyping approaches
The abstract does not show that eVLPs solve all delivery or translation challenges, and it explicitly notes future challenges remain for genome editing applications. Specific failure modes are not described in the provided evidence.; future challenges for application in genome editing are noted but not specified in the abstract
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Engineered virus-like particles are a promising delivery system class for genome editing agents.
Engineered virus-like particles enable transient delivery of ribonucleoproteins including Cas9, base editors, and prime editors.
Successive design strategies from rational engineering to directed optimization have improved engineered virus-like particle assembly, cargo stability, and editing efficiency.
Pseudotyping approaches have expanded the versatility of engineered virus-like particles for cell-type-specific targeting.
Recent preclinical studies support advancement of engineered virus-like particles toward clinical translation across diverse therapeutic applications.
Approval Evidence
1 source5 linked approval claimsfirst-pass slug engineered-virus-like-particles
Engineered virus-like particles (eVLPs) have emerged as a promising class of delivery systems for genome editing agents.
Source:
capabilitysupports
Engineered virus-like particles are a promising delivery system class for genome editing agents.
Source:
delivery mechanismsupports
Engineered virus-like particles enable transient delivery of ribonucleoproteins including Cas9, base editors, and prime editors.
Source:
engineering improvementsupports
Successive design strategies from rational engineering to directed optimization have improved engineered virus-like particle assembly, cargo stability, and editing efficiency.
Source:
targeting scopesupports
Pseudotyping approaches have expanded the versatility of engineered virus-like particles for cell-type-specific targeting.
Source:
translational potentialsupports
Recent preclinical studies support advancement of engineered virus-like particles toward clinical translation across diverse therapeutic applications.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts eVLPs with viral vectors and nonviral platforms at a high level. It presents eVLPs as a hybrid that combines advantages from both.
Source:
The abstract contrasts eVLPs with viral vectors and nonviral platforms at a high level. It presents eVLPs as a hybrid that combines advantages from both.
Source-backed strengths
efficient cellular entry; safety advantages of nonviral platforms; supports transient delivery; versatility can be expanded by pseudotyping
Source:
efficient cellular entry
Source:
safety advantages of nonviral platforms
Source:
supports transient delivery
Source:
versatility can be expanded by pseudotyping
Compared with Adeno-associated virus
The abstract contrasts eVLPs with viral vectors and nonviral platforms at a high level. It presents eVLPs as a hybrid that combines advantages from both.
Shared frame: source-stated alternative in extracted literature
Strengths here: efficient cellular entry; safety advantages of nonviral platforms; supports transient delivery.
Relative tradeoffs: future challenges for application in genome editing are noted but not specified in the abstract.
Source:
The abstract contrasts eVLPs with viral vectors and nonviral platforms at a high level. It presents eVLPs as a hybrid that combines advantages from both.
Compared with dengue enveloped viral-like particle vaccine prototype
The abstract contrasts eVLPs with viral vectors and nonviral platforms at a high level. It presents eVLPs as a hybrid that combines advantages from both.
Shared frame: source-stated alternative in extracted literature
Strengths here: efficient cellular entry; safety advantages of nonviral platforms; supports transient delivery.
Relative tradeoffs: future challenges for application in genome editing are noted but not specified in the abstract.
Source:
The abstract contrasts eVLPs with viral vectors and nonviral platforms at a high level. It presents eVLPs as a hybrid that combines advantages from both.
Ranked Citations
- 1.